The Technical Analyst
Ocugen Inc [OCGN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ocugen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-8.33% $1.320
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 339.67 mill |
| EPS: | -0.260 |
| P/E: | -5.08 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 257.33 mill |
| Avg Daily Volume: | 8.87 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.08 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.86x |
| Company: PE -5.08 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.640 (-148.50%) $-1.960 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.127 - 1.513 ( +/- 14.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
| 2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
| 2023-09-15 | Breininger Michael | Buy | 0 | |
| 2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
| 2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
| INSIDER POWER |
|---|
| 65.02 |
| Last 96 transactions |
| Buy: 10 862 012 | Sell: 2 992 475 |
Forecast:
16:00 - $1.320
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.320
Forecast 2: 16:00 - $1.320
Forecast 3: 16:00 - $1.320
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.320 (-8.33% ) |
| Volume | 8.01 mill |
| Avg. Vol. | 8.87 mill |
| % of Avg. Vol | 90.27 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OCGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.527 | N/A | Active |
|---|
OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Latest Press Releases
2024-04-18 09:00:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Ocugen, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / april 18, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ocugen, inc. ("ocugen" or "the company") (nasdaq:ocgn) for for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between may 8, 2020 and april 1, 2024, inclusive (the "class period"), are encouraged to contact the firm before june 10, 2024.
2024-04-17 23:00:00 - Press Release
Rosen, The First Filing Firm, Encourages Ocugen, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action First Filed By The Firm - Ocgn
New york , april 17, 2024 /prnewswire/ -- why: rosen law firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ocugen, inc. (nasdaq: ocgn) between may 8, 2020 and april 1, 2024, both dates inclusive (the "class period"). a class action has already been filed.
2024-04-17 13:51:00 - Press Release
Important Deadline Notice: The Schall Law Firm Encourages Investors In Ocugen, Inc. With Losses To Contact The Firm
Los angeles , april 17, 2024 /prnewswire/ -- the schall law firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ocugen, inc. ("ocugen" or "the company") (nasdaq: ocgn) for for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between may 8, 2020 and april 1, 2024, inclusive (the "class period"), are encouraged to contact the firm before june 10, 2024.
2024-04-16 22:15:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Ocugen, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / april 16, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ocugen, inc. ("ocugen" or "the company") (nasdaq:ocgn) for for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between may 8, 2020 and april 1, 2024, inclusive (the "class period"), are encouraged to contact the firm before june 10, 2024.
2024-04-15 12:00:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Ocugen, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / april 15, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ocugen, inc. ("ocugen" or "the company") (nasdaq:ocgn) for for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between may 8, 2020 and april 1, 2024, inclusive (the "class period"), are encouraged to contact the firm before june 10, 2024.
Latest News
2024-04-08 13:17:04 - Zacks Investment Research
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
2024-04-08 10:57:49 - InvestorPlace
Why Is Ocugen (OCGN) Stock Up 7% Today?
Ocugen (NASDAQ: OCGN ) stock rose about 10% over the weekend. This comes after the company won U.S. Food and Drug Administration (FDA) clearance to advance its rare eye disease treatment to a Phase 3 trial.
2024-04-07 04:06:09 - Invezz
Ocugen stock price is flying: beware of this crucial OCGN risk
Ocugen (NASDAQ: OCGN) stock price has been one of the best-performing companies in Wall Street this year. It has jumped by more than 218% in 2024, beating some of the best-known brands like Nvidia and Amazon.
2024-04-05 15:30:58 - InvestorPlace
OCGN Stock Alert: Why Is Ocugen Up 20% Today?
Biotechnology firm Ocugen (NASDAQ: OCGN ) — which specializes in developing gene therapies to address blindness diseases — saw its shares move higher on an encouraging clinical development. An advisory committee responsible for overseeing safety matters approved Ocugen to use a medium dosage of its retinal therapeutic.
2024-04-02 15:15:23 - InvestorPlace
OCGN Stock Falls Ocugen Must Restate Its Financials
Shares of once high-flying biotech company Ocugen (NASDAQ: OCGN ) are seeing some selling pressure again today. At the time of writing, OCGN stock is down over 9% on a business update provided by the company.
2024-04-01 17:43:00 - GlobeNewsWire
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to provide a business update with certain financials for the year ending December 31, 2023 at 8:30 a.m. ET on Tuesday, April 2, 2024.
2024-03-25 11:58:16 - InvestorPlace
Why Is Ocugen (OCGN) Stock Up 20% Today?
Ocugen (NASDAQ: OCGN ) stock is up on Monday as investors celebrate an update on class action lawsuit that the clinical-stage biopharmaceutical company was facing. This lawsuit came from investors who believe the company misled them.
2024-03-25 07:32:00 - InvestorPlace
3 Stocks Under $5 Ready to Outpace the Market
Finding hidden jewels in the stock market ready for explosive development — especially stocks under $5 — is like finding hidden treasure on the ocean floor. Out of all the alternatives, three companies stand out as strong candidates.
2024-03-22 09:31:00 - Market Watch
Ocugen's stock climbs as it beats back investor claims on COVID vaccine
Ocugen Inc. shares OCGN, +12.51% climbed 9% early Friday after a federal appeals court on Thursday upheld a lower court's ruling against shareholders who alleged the biotech company misled investors about its COVID-19 vaccine.
2024-03-07 05:28:00 - The Motley Fool
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Novavax and Ocugen were early contenders in the coronavirus vaccine race -- but didn't meet investors' expectations in that market. As a result, shares of both companies have plummeted.